Reviews
COVID-19: the new challenge for rheumatologists. One year later
I. Puxeddu1, F. Ferro2, E. Bartoloni3, E. Elefante4, C. Baldini5, C.A. Scirè6, R. Talarico7, P. Migliorini8, M. Mosca9, S. Bombardieri10
- Clinical Immunology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy. ilaria.puxeddu@unipi.it
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
- Rheumatology Unit, Department of Medicine, University of Perugia, Italy.
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
- Rheumatology Unit, Department of Medical Sciences, University of Ferrara, Italy.
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
- Clinical Immunology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
- University of Pisa, Italy.
CER14476
2021 Vol.39, N°1
PI 0203, PF 0213
Reviews
Free to view
(click on article PDF icon to read the article)
PMID: 33555253 [PubMed]
Received: 30/01/2021
Accepted : 05/02/2021
In Press: 05/02/2021
Published: 05/02/2021
Abstract
At the beginning of COVID-19, we underlined that this pandemic was a new challenge for rheumatologists. On the one hand, it was necessary to clarify the impact of this new viral disease on the natural history of many rheumatic diseases and, on the other hand, to define the beneficial or harmful effects of the synthetic or targeted therapies used for their treatment. In addition, we have postulated that in view of the common pathogenetic mechanisms involved, the therapeutic armamentarium currently employed in the management of viral or idiopathic systemic autoimmune rheumatic diseases could be useful to control the “cytokine storm” induced by SARS-COV-2. One year later, in the present review we have analysed the progress of the knowledge on both these aspects and updated the algorithms initially proposed for a rational use of the synthetic and targeted anti-inflammatory and immunomodulatory agents in the management of COVID-19.
